Efficacy and advantages of modified Traditional Chinese Medicine treatments based on “kidney reinforcing” for chronic aplastic anemia: a randomized controlled clinical trial  by Dijiong, Wu et al.
TOPIC
JTCM |www. journaltcm. com August 15, 2016 |Volume 36 | Issue 4 |
Online Submissions: http://www.journaltcm.com J Tradit Chin Med 2016 August 15; 36(4): 434-443
info@journaltcm.com ISSN 0255-2922
© 2016 JTCM. All rights reserved.
CLINICAL STUDY
Efficacy and advantages of modified Traditional Chinese Medicine
treatments based on "kidney reinforcing" for chronic aplastic ane-
mia: a randomized controlled clinical trial
Wu Dijiong, Shen Yiping, Ye Baodong, Fang Bingmu, Lin Shengyun, Chen Zhilu, Jiang Huifang, Feng Changwei,
He Lüyuan, Gao Yanting, Liu Yonglin, Liu Yonghua, Zhu Jiajia, Wu Liqiang, Shao Keding, Zhou Yuhong
aa
Wu Dijiong, Shen Yiping, Ye Baodong, Lin Shengyun,
Gao Yanting, Liu Yonglin, Zhu Jiajia, Wu Liqiang, Shao
Keding, Zhou Yuhong, Department of Hematology, Zheji-
ang Provincial Hospital of Traditional Chinese Medicine,
Hangzhou 310006, China
Fang Bingmu, Liu Yonghua, Department of Hematology,
People' s Hospital of Lishui City, Lishui 323000, China
Chen Zhilu, Jiang Huifang, Department of Hematology,
Tongde Hospital of Zhejiang Province, Hangzhou 310007,
China
Feng Changwei, Department of Hematology, Taizhou Hos-
pital of Zhejiang Province, Taizhou 318000, China
He Lüyuan, Department of Hematology, Jinhua Hospital of
Traditional Chinese Medicine, Jinhua 321017, China
Supported by Special Item of Important Disease of Zheji-
ang Province Traditional Chinese Medicine Sic-Tech Innova-
tion Platform (Effect and Mechanism of Traditional Chinese
Medicine on the Treatment of Aplastic Anemia and the
Funding of Traditional Chinese Medicine Assessment Criteri-
on, No. 2009ZDJB01); Subject of Key Sic-Tech Innovation
Team of Zhejiang Province (Clinical Study on Treatment of
Chronic Aplastic Anemia by Tonifying Kidney and Promot-
ing Blood Circulation, No. 2011R09042-02); Special Research
Funds for Traditional Chinese Medicine Industry (Effect of
Traditional Chinese Medicine on the Treatment of Risk Fac-
tors of Chronic Aplastic Anemia, No. 201107001); Special Re-
search Funds for Traditional Chinese Medicine Industry (Clin-
ical Study on the Diagnosis and Treatment of Aplastic Ane-
mia Based on the Syndrome And Stage Differentiation, No.
201407001); Zhejiang Provincial Traditional Chinese Medi-
cine Administration Bureau Program (Establishment of Tradi-
tional Chinese Medicine Clinical Pathway on Aplastic Ane-
mia, No. 2010ZA039)
Correspondence to: Prof. Shen Yiping, Department of He-
matology, Zhejiang Provincial Hospital of Traditional Chi-
nese Medicine, Hangzhou 310006, China. shenyp_@126.
com; Prof. Ye Baodong, Department of Hematology, Zheji-
ang Provincial Hospital of Traditional Chinese Medicine,
Hangzhou 310006, China. 13588453501@163.com
Telephone: +86-571-87073569
Accepted: February 22, 2016
Abstract
OBJECTIVE: To compare the efficacy of modified
treatments based on "kidney reinforcing" in the
management of chronic aplastic anemia (CAA), and
explore their advantages and specialties.
METHODS: One hundred and eleven patients with
CAA were randomly divided into three groups: kid-
ney reinforcing alone (KA), "kidney reinforcing and
Qi tonifying" (KQ), and "kidney reinforcing and
blood circulation invigorating" (KC). Normal and
positive control groups were also formed. All pa-
tients were treated for 6 months (two courses). He-
mograms, Traditional Chinese Medicine (TCM) syn-
drome scores, and therapeutic effects were as-
sessed, and changes in T-lymphocyte subsets, regu-
latory T cells and cytokines were detected.
RESULTS: The KQ and KC groups had lower TCM
syndrome scores than the positive control group af-
ter 6 months (P < 0.05). The KQ group had a higher
overall efficacy than the positive control group af-
ter 3 months (P < 0.05), while platelet counts in-
creased in the KC group after 6 months (P < 0.05).
CD3+ T-lymphocyte ratios decreased only in the KQ
group, while CD3 + CD4 + CD8 − Tlymphocytes in-
creased only in the KC group after 6 months (P <
0.05). Levels of interferon-γ, tumor necrosis fac-
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tor-α, interleukin (IL)-2 and IL-6 decreased and lev-
els of IL-4 and IL-10 increased in all treated groups
after 6 months. Levels of IL-6 in the KQ and KC
groups were lower than those in the positive con-
trol group (P < 0.05).
CONCLUSION: Treatments based on kidney rein-
forcing have a rebalancing effect on cytotoxic and
T helper cells, and regulate expression of interfer-
on-γ, IL-2, IL-6 and IL-4. KQ may be more effective in
treating CAA, and KC may have an advantage in
platelet recovery.
Key words: Anemia, aplastic; Reinforcing Qi
strengthening kidney; Reinforcing kidney nourish-
ing blood; Randomized controlled trial
INTRODUCTION
Aplastic anemia (AA) is a commonly encountered he-
matological disease that presents with bone marrow
failure and pancytopenia.1 AA can be divided into acute
AA and chronic AA (CAA), according to the develop-
ment and severity of the disease. CAA characteristics in-
clude long disease course, predisposition to relapse and
refractoriness, and poor quality of life; these are as-
cribed to the maintenance of drug therapy and the per-
sistent risk of infection and bleeding. It is reported that
the incidence of AA is 2/106 per year in western coun-
tries, while in China, the rate is nearly triple (~7.4 /
106); CAA comprises almost 80% of these cases.2
In Traditional Chinese Medicine (TCM), AA is called
"Suilao", which means exhaustion of marrow. The ap-
plication of TCM in the treatment of AA began 50
years ago. Before the 1980s, it was claimed that treat-
ment of CAA should be based on "spleen (Pi)", and
"fortify the spleen and replenish Qi" was emphasized,
although limited effectiveness was achieved. After the
1980s, the consensus was that treatment of CAA
should be based on "kidney reinforcing", and the meth-
od of "kidney warming and essence replenishing" was
recommended.3 To date, many studies have explored
the mechanisms behind "kidney deficiency" in the de-
velopment of AA, such as "Qi deficiency", "Yin defi-
ciency", "blood stasis", and "stagnation of liver-Qi",4
yet no consensus has been achieved, and the actual effi-
cacy is not well established.
In our center, we treat CAA with the unification of dis-
ease and syndrome differentiation. Reinforcing Qi and
activating blood is highlighted, followed by kidney re-
inforcing.5,6 To clarify and compare the efficacy and ad-
vantages of modified TCM treatments based on kidney
reinforcing with or without "Qi tonifying" or "blood
activating", a multicenter randomized controlled trial
was conducted.
MATERIALS ANDMETHODS
General data
From April 2010 to April 2012, 158 patients with
CAA visited Zhejiang Provincial Hospital of Tradition-
al Chinese Medicine, People's Hospital of Lishui,
Tongde Hospital of Zhejiang Province, Taizhou Hospi-
tal of Zhejiang Province, and Jinhua Hospital of Tradi-
tional Chinese Medicine. One hundred and eleven of
these patients were enrolled in this study (31 patients
were excluded for not meeting the inclusion criteria,
and the other 16 declined to receive TCM treatment).
Simple randomization was used following a comput-
er-generated random number sequence. Participants
and practitioners were not blinded to allocation. All
111 patients were randomly divided into three groups
of 37: kidney reinforcing alone (KA), kidney reinforc-
ing and Qi tonifying (KQ), and kidney reinforcing and
blood circulation invigorating (KC). Fifteen healthy
people were enrolled in a normal control group, and
another 16 patients without TCM treatment were en-
rolled as a positive control group. This study followed
the Declaration of Helsinki and was approved by the
Institution Committee of Ethics of Zhejiang Tradition-
al Chinese Medicine Hospital. All the patients gave in-
formed consent to treatment.
Diagnostic standards
Diagnostic standards in Western Medicine: AA was di-
agnosed according to the "Diagnosis and Treatment
Standards of Hematology Disease (third edition)".7 Pa-
tients with CAA present with: (a) slower progression
than acute AA, and slight manifestation of anemia, in-
fection and hemorrhage; (b) decreased hemoglobin, re-
ticulocyte, neutrophil and platelet counts (but not to
the same extent as that seen in acute AA); (c) decreased
proliferation of two or three hematopoietic cell lines in
the bone marrow, dysplasia at more than one site, sig-
nificantly reduced numbers of megakaryocytes, and in-
creased numbers of nonhematopoietic cells; and (d) a
type of severe AA diagnosed upon confirmation of pro-
gressive disease.
Kidney Yang deficiency syndrome differentiation in
TCM: Patients presented with soreness and weakness
in the waist and knees, cold body and limbs, pale com-
plexion, poor appetite, diarrhea, plump tongue with
whitish and slippery furring and bearing dental inden-
tations on the margin, and a forceless deep pulse,
which were diagnosed with kidney Yang deficiency ac-
cording to "Guidelines for Diagnosis and Treatment of
Common Internal Disease in Chinese Medicine".8
Standards for inclusion
(a) Patients conformed to AA diagnostic criteria in
Western Medicine and kidney Yang deficiency syn-
drome differentiation in TCM. (b) Patients with no
other diseases present with pancytopenia, such as my-
elodysplastic syndrome, primary myelofibrosis, paroxys-
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mal nocturnal hemoglobinuria and leukemia. (c) Pa-
tients aged 14-80 years. (d) Patients voluntarily partici-
pating in the study and giving signed informed con-
sent.
Standards for exclusion
(a) Patients who were pregnant or breastfeeding. (b) Pa-
tients with other serious diseases (cardiovascular and
cerebrovascular diseases, liver and renal dysfunction, se-
vere infection, and mental illness). (c) Patients present-
ing with other hematological disease or malignancy. (d)
Patients presenting with complex TCM syndrome.
Therapies
Treatment based on TCM: (a) Patients in the KA
group were treated with modified "Yougui decoction",
which comprised Prepared Dihuang (Radix Rehmanni-
ae) 15 g, Rougui (Cortex Cinnamomi Cassiae) 3 g, Fuzi
(Radix Aconiti Lateralis Preparata) 4 g, Yinyanghuo
(Herba Epimedii Brevicornus) 8 g, Xianmao (Rhizoma
Curculiginis) 8 g, Lujiaojiao (Colla Cornus Cervi) 10 g,
Duzhong (Cortex Eucommiae) 12 g, Shanzhuyu (Fruc-
tus Macrocarpii) 15 g, Prepared Heshouwu (Radix
Polygoni Multiflori) 12 g, Huangjing (Rhizoma Polygo-
nati Sibirici) 15 g, Shanyao (Rhizoma Dioscoreae Oppos-
itae) 15 g, Gouqizi (Fructus Lycii) 15 g, Chenpi (Peri-
carpium Citri Reticulatae), and Sharen (Fructus Amomi)
3 g. (b) Patients in the KQ group were treated with
Yougui decoction combined with Huangqi (Radix As-
tragali Mongolici) 50 g, Dangshen (Radix Codonopsis)
12 g and Baizhu (Rhizoma Atractylodis Macrocephalae)
15 g. (c) Patients in the KC group were treated with
Yougui decoction combined with Danggui (Radix An-
gelicae Sinensis) 20 g, Chishao (Radix Paeoniae Rubra)
6 g, Taoren (Semen Persicae) 6 g, Danshen (Radix Salvi-
ae Miltiorrhizae) 10 g and Jixueteng (Caulis Spatholobi)
10 g.
Maintenance of Western Medicine: all patients en-
rolled continued with their Western Medicine treat-
ment protocols: androgen, including stanozolol
(4-6 mg/day tid per os), andriol (80-120 mg/day per
os), and others (such as danazol and testosterone propi-
onate). The dose of cyclosporine A was 3-6 mg·kg－1·
d － 1, and the serum concentration was maintained at
150-250 ng/L.
Supporting treatment: patients received erythrocyte sus-
pension transfusion when hemoglobin was < 75 g/L or
if they had significant symptoms of anemia even when
hemoglobin was just below 80 g/L. Platelet transfusion
and hemostatic treatment were administered when
platelet count was < 5.0 × 109/L (with no bleeding risk
factor) or < 2.0 × 1010/L with bleeding risk factors. An-
ti-infective therapy was followed according to the site
and severity of infection.
Treatment period: each treatment course lasted 3 mon-
ths, and two courses were followed.
Indexes and methods for observation
Common index: gender, age, body height and weight,
vital signs, history of present illness, history of past ill-
ness, and frequency of blood transfusion in the last 3
months were recorded.
Safety index: routine tests of blood, urine and stools,
stool occult blood, abdominal ultrasound, electrocardi-
ography, liver and renal function, and serum concentra-
tion of cyclosporine (if necessary) were assessed at the
beginning and end of the trial.
Curative effect index: (a) Hemogram. Patients were
checked routinely for blood and reticulocytes every 2
weeks. (b) Assessment of TCM syndrome. TCM syn-
drome scores of all patients were calculated according
to the Scheme of Clinical Diagnosis and Treatment of Sui-
lao, published by the State Administration of Tradition-
al Chinese Medicine in 2010. Symptoms of the major
syndrome include pale face, dizziness, palpitations, and
shortness of breath, while symptoms of the minor syn-
drome include feverish palms and soles, hectic fever
and night sweating, dipsia, yellow urine, cold body, an-
orexia, and diarrhea. According to the severity (light,
moderate or severe) of main and minor syndromes, 0,
2, 4 and 6 points or 0, 1, 2 and 3 points were scored re-
spectively during the statistical process.
Efficacy evaluation criteria: criteria in Western Medi-
cine. (a) Basically cured: disappearance of anemia and
bleeding, with a hemoglobin level of 120 and 100 g/L
in male and female patients, respectively, without recov-
ery within 1 year. (b) Remission: disappearance of ane-
mia and bleeding, with a hemoglobin level of 120 and
100 g/L in male and female patients, respectively. The
white blood cell (WBC) count reaches 3.5 × 109/L
with an improvement in platelet count. Disease stays
stable or improved in the following 3 months. (c) Im-
proved: major improvement in the appearance of ane-
mia and bleeding, transfusion independent, with a >
30 g/L increase of hemoglobin. Disease stays stable
for ≥ 3 months. All three criteria should be assessed
without transfusion in the last 3 months. (d) Invalid:
symptoms and hemogram have not met the definition
of improved after therapy. Criteria in TCM. [Score Im-
proving Rate (SIR) = (score before treatment − score
after treatment) / score before treatment × 100%] (a)
Clinical recovery: disappearance or basically disappear-
ance of TCM clinical symptoms and signs, with SIR ≥
90%. (b) Notable efficacy: disappearance or basic dis-
appearance of TCM clinical symptoms and signs, with
SIR < 90% and ≥ 70%. (c) Efficacy: improvement of
TCM clinical symptoms and signs, with SIR < 70%
and ≥ 30%. (d) Invalid: no improvement in TCM clini-
cal symptoms and signs, with SIR < 30%.
Immune function detection: T-lymphocyte subsets, reg-
ulatory T cells (CD4 + CD25 + FoxP3 +), were detect-
ed before and after the trial, and cytokines [e.g., inter-
leukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor
(TNF)-α and interferon (IFN)-γ] were detected every
3 months. All these indices were detected in the De-
partment of Clinical Laboratory of Zhejiang Provincial
Hospital of Traditional Chinese Medicine. T-lympho-
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cyte monoclonal antibodies were purchased from BD
Pharmingen (San Diego, CA, USA) and the human cy-
tokine fluorescent reagent kits were purchased from
Millipore (Boston, MA, USA).
Side effect observation: commonly encountered side ef-
fects ascribe to the application of immune suppression
and androgen, including gastrointestinal adverse reac-
tions, secondary hypertension, polytrichia, gingival hy-
perplasia, rash, liver and renal dysfunction, and hand
tremor, were observed.
Statistical analysis
The compiled data were first entered into an Excel
spreadsheet, and then read into SPSS version
15.0 (SPSS, Chicago, IL, USA) biometric statistical
software for further analysis. Normal data were ex-
pressed as the mean (standard deviation), and non-nor-
mal data were expressed as the median (interquartile
range). Variance and pairwise comparisons were used
for normal data, whereas non-normal data were subject-
ed to nonparametric tests, wherein the Kruskal-Wallis
H test was used for pairwise comparisons and the
Mann-Whitney U test was used for multiple compari-
sons. P < 0.05 was considered statistically significant
andP<0.01was considered statistically very significant.
RESULTS
Features of patients
During the observation (Figure 1), 17 of 111 patients
were withdrawn: four in the KA group; six in the KQ
group; and seven in the KC group. Patients in the KA
group (n = 33) were aged 15-60 years (median age
29.5 years), and included 12 men and 21 women. Pa-
tients in the KQ group (n = 31) were aged 16-67 years
(median age 36.0 years), and included 11 men and 20
women. Patients in the KC group (n = 30) were aged
15-74 years (median age 35.5 years), and included
eight men and 17 women. The positive control group
(n = 16) was aged 17-59 years (median age 35.5 years),
and included five men and 11 women. The normal
control group (n = 15) was aged 24-50 years (median
age 31.0 years), and included seven men and eight
women. There was no significant difference in general
data among the groups (P > 0.05) (Table 1).
Comparison of hemograms
There were no differences in the hemograms of pa-
tients in the four groups before treatment (P > 0.05).
After 3 months, the WBC counts increased significant-
ly only in the KQ group, from 2.9 ± 1.1×109/L to 3.7
± 1.7 × 109/L (P < 0.05), which was higher than that
in the positive control and KC groups (2.5 ± 1.0 × 109/L
and 2.6 ± 0.6 × 109/L, respectively) (P < 0.05). The lev-
el of hemoglobin (Hb) increased in all three TCM
groups combined (KA, KQ and KC) (P < 0.05), where-
as in the KQ group, the difference was notable only
when compared with Hb levels in the positive control
group (P < 0.05). No differences were observed among
all three TCM groups combined. Platelet counts did
not increase in any group at the end of the first course
of treatment. After 6 months, the increase in WBC
Patients decline to
receive TCM (n = 16)
Excluded (n = 47)
Notmeeting inclusion criteria (n =31)
Decline to receive TCM (n = 16)
Assessed for eligibility (n = 158)
Zhejiang Provincial Hospital of TCM (n = 45)
People's Hospital of Lishui (n = 26)
Tongde Hospital of Zhejiang Province (n = 12)
Taizhou Hospital of Zhejiang Province (n = 8)
Jinhua Hospital of TCM (n = 10)
Randomized (n = 111)
Maintenance of Western Medicine
Compared group
received maintenance of
Western Medicine (n = 16)
Allocated to KA group
received kidney reinforcing
alone (n = 37)
Allocated to KQ group
received kidney reinforcing
and Qi tonifying (n = 37)
Allocated to KC group
received kidney reinforcing and
blood circulation invigorating
(n= 37)
Discontinued intervention for
discontinued hospital visit
(n = 0)
Discontinued intervention for
discontinued hospital visit
(n = 4)
Discontinued intervention for
discontinued hospital visit
(n = 6)
Discontinued intervention for
discontinued hospital visit (n = 7)
Analysed (n = 16) Analysed (n = 33) Analysed (n = 31) Analysed (n = 30)
Figure 1 Flow diagram of the progress through the phases of the randomized trial
TCM: Traditional Chinese Medicine.
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count was still not obvious in all groups, except the
KQ group (P < 0.05). The level of Hb increased in all
groups (P < 0.05), and it was higher when compared
with that 3 months ago only in the KQ group (P <
0.05). Platelet counts increased significantly only in
the KC group when compared with counts before treat-
ment. No differences were observed among the three
TCM groups combined (Table 2).
Comparison of therapeutic effect in Western
Medicine
After the first course of treatment (3 months), overall
efficacy (OE) was 45.5% , 61.3% , 56.7% and 33.3%
in the KA, KQ, KC and positive control groups, re-
spectively. There was a significant difference between
the KQ and positive control groups (P < 0.05). No
differences were observed among the other groups.
The OE was 69.7%, 77.4%, 80.0% and 50.0%, re-
spectively, in the KA, KQ, KC and positive control
groups after the second course of treatment (6
months), and there was improvement in the KA and
KC groups when compared with 3 months previous-
ly (P < 0.05). The OE of the KC group was higher
than that in the positive control group after 6
months' treatment (P < 0.05). No differences were
observed among the three TCM groups combined
(Table 3).
Table 1 General clinical data of patients
Group
KA
KQ
KC
Positive control
Normal control
Gender [n (%)]
Male
12 (36.4)
11 (35.5)
13 (43.3)
5 (31.2)
7 (46.7)
Female
21 (63.6)
20 (64.5)
17 (56.7)
11 (68.8)
8 (53.3)
Age (years)
29.5 (15-60)
36.0 (16-67)
29.0 (15-74)
35.5 (17-59)
31.0 (24-50)
Notes: patients with chronic aplastic anemia (CAA) were randomly divided into three groups: "kidney reinforcing alone (KA)", "kidney re-
inforcing and Qi tonifying (KQ)" and "kidney reinforcing and blood circulation invigorating (KC)". Patients in the TCM treated groups
were treated with modified "Yougui decoction", with the addition of kidney Yin tonifying herbs in KA group, Qi tonifying herbs in KQ
group and blood circulation invigorating herbs in KC group. Normal and positive control groups were also formed. Patients in normal con-
trol group were treated without anything, and patients in positive control group were treated with western medicine alone (androgen with
or without cyclosporine A for six months) respectively. All patients were treated for 6 months (two courses). The general data of the five
groups were compared with each other. Data are shown as case (%), and no significant differences were observed.
Table 2 Comparison of hemograms ( xˉ ± s)
Group
KA
KQ
KC
Positive control
Time
Before treatment
Treated with 3 months
Treated with 6 months
Before treatment
Treated with 3 months
Treated with 6 months
Before treatment
Treated with 3 months
Treated with 6 months
Before treatment
Treated with 3 months
Treated with 6 months
WBC (109/L)
2.6±0.9
2.5±0.7
3.0±0.7
2.9±1.1
3.7±1.7ac
3.6±1.5ac
2.5±1.0
2.6±0.6b
3.2±1.0
2.1±1.3
2.5±1.0
2.6±0.8
Hb (g/L)
86.2±40.3
85.1±30.8a
92.5±25.8a
82.4±25.2
90.1±26.1ac
96.1±26.4cde
72.3±25.5
78.3±22.2a
91.2±27.8a
65.1±24.9
70.0±23.7
72.0±22.0a
PLT (109/L)
32.9±23.0
39.9±30.3
43.5±38.0
32.9±45.5
40.8±58.6
45.7±52.4
31.4±24.6
35.8±40.9
51.3±47.2a
27.2±39.8
29.2±37.6
32.7±35.5
Notes: routine blood tests in the KA (kidney reinforcing alone), KQ (kidney reinforcing and Qi tonifying), KC (kidney reinforcing and
blood circulation invigorating) and positive control groups were performed before treatment and 3 and 6 months after. Patients in the
TCM treated groups were treated with modified "Yougui decoction", with the addition of kidney Yin tonifying herbs in KA group, Qi
tonifying herbs in KQ group and blood circulation invigorating herbs in KC group. Patients in positive control group were treated with
western medicine alone (androgen with or without cyclosporine A for six months). Hb: hemoglobin; PLT: platelet; WBC: white blood
cell; TCM: Traditional Chinese Medicine. aP < 0.05, dP < 0.01, compared with that before treatment in the same group; bP < 0.05, com-
pared with that in the KQ group at the same time; cP < 0.05, compared with that in the positive control group at the same time; eP < 0.05,
compared with that treated with 3 months in the same group.
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Comparison of TCM syndrome score
No differences were observed in the TCM syndrome
score of each group (KA, KQ, KC and positive control
groups) before treatment (12.2 ± 4.3, 11.9 ± 3.2, 11.7
± 4.4 and 11.6 ± 4.7, respectively, P > 0.05). All the
TCM groups combined (KA, KQ and KC) showed im-
provement in TCM syndrome when treated for 3 or 6
months. All syndrome scores decreased significantly
(P < 0.01) and more obviously after 6 months (P <
0.05). In the positive control group, the score had a no-
table decrease only after the second course of treatment
(6 months). Additionally, the score was lower in the
KQ and KC groups when compared with that in the
positive control group after 6 months (P < 0.05), while
no differences were observed among the other groups
(P > 0.05) (Table 4, Figure 2).
Comparison of therapeutic effect in TCM
OE was 57.6%, 67.7%, 60.0% and 50.0% in the KA,
KQ, KC and positive control groups, respectively, after
3 months' treatment. After the second course of treat-
ment (6 months), OE was 78.8%, 87.1%, 80.0% and
62.5%, respectively, in the four groups, and there was
an improvement in the KQ group when compared
with 3 months previously (P < 0.05). No significant
differences were observed between the three TCM
groups combined (Table 5).
Group
KA
KQ
KC
Positive control
Course of treatment
(months)
3
6
3
6
3
6
3
6
Basically cure
(n)
0
2
1
2
2
3
0
0
Remission
(n)
5
11
10
14
6
8
1
3
Improve
(n)
10
10
8
8
9
13
3
5
Invalid
(n)
18
10
12
7
13
6
12
8
Overall efficacy
[n (%)]
15 (45.5)
23 (69.7)a
19 (61.3)b
24 (77.4)
16 (56.7)
24 (80.0)ab
4 (33.3)
8 (50.0)
Notes: therapeutic effect of Western Medicine in the KA (kidney reinforcing alone), KQ (kidney reinforcing and Qi tonifying), KC (kid-
ney reinforcing and blood circulation invigorating) and positive control groups was evaluated after treatment for 3 and 6 months. Patients
in the TCM treated groups were treated with modified "Yougui decoction", with the addition of kidney Yin tonifying herbs in KA group,
Qi tonifying herbs in KQ group and blood circulation invigorating herbs in KC group. Patients in positive control group were treated with
western medicine alone (androgen with or without cyclosporine A for six months). TCM: Traditional Chinese Medicine. aP < 0.05, com-
pared with that after 3 months' treatment in the same group; bP < 0.05, compared with that in the positive control group at the same time.
Table 3 Comparison of therapeutic effect inWestern Medicine
Group
KA
KQ
KC
Positive control
Time
Before treatment
Treated with 3 months
Treated with 6 months
Before treatment
Treated with 3 months
Treated with 6 months
Before treatment
Treated with 3 months
Treated with 6 months
Before treatment
Treated with 3 months
Treated with 6 months
Syndrome score
12.2±4.3
9.6±3.6a
6.6±3.0ab
11.9±3.2
7.6±3.9a
5.7±3.2abc
11.7±4.4
8.4±3.4a
5.9±2.1abc
11.6±4.7
10.3±4.3
7.8±3.9ab
Notes: the TCM syndrome scores in the KA (kidney reinforcing alone), KQ (kidney reinforcing and Qi tonifying), KC (kidney reinforcing
and blood circulation invigorating) and positive control groups were evaluated before treatment and 3 and 6 months after. Patients in the
TCM treated groups were treated with modified "Yougui decoction", with the addition of kidney Yin tonifying herbs in KA group, Qi
tonifying herbs in KQ group and blood circulation invigorating herbs in KC group. Patients in positive control group were treated with
western medicine alone (androgen with or without cyclosporine A for six months). TCM: Traditional Chinese Medicine. aP < 0.01, com-
pared with that before treatment in the same group; bP < 0.05, compared with that after 3 months' treatment in the same group; cP < 0.05,
compared with that in the positive control group at the same time.
Table 4 Comparison of TCM syndrome score ( xˉ ± s)
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Comparison of T-lymphocyte subsets and regulatory
T cells
No differences in the ratio of T-lymphocyte subsets
and regulatory T cells were observed among the three
TCM groups combined and the positive control
group. The ratio of CD3+ T lymphocytes decreased on-
ly in the KQ group after 6 months of treatment, while
CD3+CD4+CD8− T lymphocytes increased only in
the KC group after 6 months of treatment (P < 0.05).
All the TCM groups combined had a decreased level of
CD3+CD4−CD8+ T lymphocytes (P < 0.01), while it
increased in the positive control group after 6 months
of treatment (P < 0.01). The CD3 + CD4 + CD25 +
FoxP3+ regulatory T cell/CD3+CD4+ ratio decreased
in all treated groups after 6 months, while no signifi-
cant differences were observed (Table 6).
Comparison of cytokines
Levels of IFN-γ, TNF-α, IL-2, IL-4, IL-6 and IL-10
were higher in patients with CAA when compared
with those in the normal control group, while no sig-
nificant differences were observed except for IL-2 and
IL-4 levels (P < 0.05). Cytokine expression in all treat-
ment groups did not show a significant change after 3
months (P > 0.05). After two courses of treatment (6
months), the levels of IFN-γ, TNF-α, IL-2 and IL-6
decreased, with further increases in IL-4 and IL-10 in
all treated groups. IFN-γ, IL-2 and IL-6 levels in the
TCM combined groups (KA, KQ and KC groups)
were significantly lower than before treatment (P <
0.05 or P < 0.01), and IL-4 increased in all treated
groups (P < 0.05). When compared with 3 months pre-
viously, IFN-γ, IL-2 and IL-6 in the KQ and KC
groups and IL-4 in the KQ, KC and positive control
groups had changed after 6 months (P < 0.05). In addi-
tion, the level of IL-6 in the KQ and KC groups after 6
months was lower than in the positive control group.
No significant differences were observed between the
three TCM groups combined (Table 7).
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Figure 2 TCM syndrome scores of the KA group, KQ group, KC group and the positive control group were evaluated before and 3
and 6 months after treatment
Patients in the TCM treated groups were treated with modified "Yougui decoction", with the addition of kidney Yin tonifying herbs
in KA group, Qi tonifying herbs in KQ group and blood circulation invigorating herbs in KC group. Patients in positive control
group were treated with western medicine alone (androgen with or without cyclosporine A for six months). TCM: Traditional Chi-
nese Medicine; KA: kidney reinforcing alone; KQ: kidney reinforcing and Qi tonifying; KC: kidney reinforcing. aP < 0.01, compared
with that before treatment in the same group; bP < 0.05, compared with that at 3 months after treatment in the same group; cP <
0.05, compared with that in the positive control group at the same time.
a
ab a abc
a
abc
ab
Group
KA
KQ
KC
Positive control
Course of treatment
(month)
3
6
3
6
3
6
3
6
Clinical recovery
(n)
1
2
2
4
1
2
0
0
Notable efficacy
(n)
4
6
5
7
3
8
2
3
Efficacy
(n)
14
18
12
16
14
14
6
7
Invalid
(n)
14
7
10
4
12
6
8
6
Overall efficacy
[n (%)]
19 (57.6)
26 (78.8)
19 (67.7)
27 (87.1)ab
18 (60.0)
25 (80.0)a
8 (50.0)
10 (62.5)
Notes: the therapeutic effects of TCM in the KA (kidney reinforcing alone), KQ (kidney reinforcing and Qi tonifying), KC (kidney rein-
forcing and blood circulation invigorating) and positive control groups were evaluated after treatment for 3 and 6 months. Patients in the
TCM treated groups were treated with modified "Yougui decoction", with the addition of kidney Yin tonifying herbs in KA group, Qi
tonifying herbs in KQ group and blood circulation invigorating herbs in KC group. Patients in positive control group were treated with
western medicine alone (androgen with or without cyclosporine A for six months). TCM: Traditional Chinese Medicine. aP < 0.05, com-
pared with that after 3 months' treatment in the same group; bP < 0.05, compared with that in the positive control group at the same time.
Table 5 Comparison of therapeutic effect of TCM
440
JTCM |www. journaltcm. com August 15, 2016 |Volume 36 | Issue 4 |
Wu DJ et al. / Clinical Study
Comparison of side effects
Incidence of gastrointestinal adverse reaction, polytrich-
ia, gingival hyperplasia, and rash ranged from 37.5%
to 62.5% in the positive control group. The incidence
was higher than for other side effects: secondary hyper-
tension 12.5% , liver dysfunction 18.75% , renal dys-
function 6.25% , and hand tremor 18.75% . With
TCM treatment, the incidence of gastrointestinal ad-
verse reaction, polytrichia, and rash decreased in the
KA, KQ and KC groups (P < 0.01), and the develop-
ment of liver dysfunction and hand tremor also de-
creased in the KC group (P < 0.05). No notable differ-
ences in the incidence of side effects were observed
among the three TCM groups combined (Table 8).
DISCUSSION
According to TCM, long-term disease is always accom-
Groups
KA
KQ
KC
Positive control
Normal reference value
Time
Before treatment
After 6 months
Before treatment
After 6 months
Before treatment
After 6 months
Before treatment
After 6 months
-
CD3+
77.4±7.7
76.1±8.5
78.5±8.4
75.8±8.9a
80.8±6.1
81.6±8.5
75.3±14.5
80.4±7.5
58.4-81.6
CD3+CD4+CD8-
38.7±9.0
37.8±7.8
38.1±8.3
38.4±7.8
41.4±11.7
49.1±5.8a
34.6±9.4
40.5±9.1
24.9-45.6
CD3+CD4-CD8+
30.3±10.5
29.9±9.9b
29.9±7.6
29.9±7.4b
30.6±9.6
26.1±8.4b
33.2±10.5
34.2±9.2 b
16.4-33.8
CD3+CD4+CD25+
FoxP3+/CD3+CD4+
3.2±4.0
1.1±1.3
3.4±4.6
1.5±1.3
3.2±3.7
1.5±1.3
3.0±3.7
1.1±0.7
1.1-7.8
Notes: comparison of T-lymphocyte subsets and regulatory T cells in the KA (kidney reinforcing alone), KQ (kidney reinforcing and Qi
tonifying), KC (kidney reinforcing and blood circulation invigorating) and positive control groups was performed before and 6 months af-
ter treatment. Patients in the TCM treated groups were treated with modified "Yougui decoction", with the addition of kidney Yin tonify-
ing herbs in KA group, Qi tonifying herbs in KQ group and blood circulation invigorating herbs in KC group. Patients in positive control
group were treated with western medicine alone (androgen with or without cyclosporine A for six months). TCM: Traditional Chinese
Medicine. aP < 0.05, bP < 0.01, compared with that before treatment in the same group.
Table 6 Comparison of T-lymphocyte subsets and regulatory T cells in different groups (%, xˉ ± s)
Group
KA
KQ
KC
Positive
control
Norma
control
Time
Before treatment
Treated with 3 months
Treated with 6 months
Before treatment
Treated with 3 months
Treated with 6 months
Before treatment
Treated with 3 months
Treated with 6 months
Before treatment
Treated with 3 months
Treated with 6 months
-
IFN-γ
5.23±4.42
4.04±3.88
2.01±2.19a
4.83±8.26
3.68±5.00
1.90±2.43ab
4.14±3.86
4.26±4.64
2.37±1.40ab
5.51±3.39
4.35±3.98
2.11±3.01a
3.06±5.04
TNF-α
6.21±4.93
4.77±2.54
4.38±4.50
6.97±5.28
4.41±2.81
4.48±5.17
5.97±4.70
4.85±2.76
4.13±2.81
5.88±4.84
4.78±3.18
4.28±3.18
5.49±2.51
IL-2
3.22±2.91c
2.32±1.79c
1.37±2.43a
2.89±2.36c
2.01±2.09
0.84±0.71bd
3.03±2.35c
2.11±2.13
0.91±1.08ab
3.04±2.11c
2.61±1.95c
1.21±1.64
1.19±1.85
IL-4
0.77±0.40c
0.80±0.48c
0.92±0.38ac
0.74±0.65c
0.78±0.38e
0.98±0.47abc
0.79±0.46c
0.77±0.50c
1.20±2.37abc
0.68±0.55c
0.68±0.69c
0.99±0.41abc
0.24±0.64
IL-6
3.12±4.62
2.32±1.96
1.82±1.02a
3.51±5.10
2.66±2.22
1.10±0.12abe
2.84±4.77
2.68±3.06
1.16±1.08abe
4.10±3.20
3.28±4.77
1.82±2.11a
1.43±2.14
IL-10
8.48±5.95
9.23±5.46
10.92±6.33
8.08±7.28
9.75±6.57
10.21±7.23
8.50±7.82
10.77±7.73
11.43±6.52
7.99±10.21
8.56±13.22
10.05±14.36
7.63±3.71
Table 7 Comparison of cytokines in different groups (pg/mL, xˉ ± s)
Notes: comparison of cytokines in the KA (kidney reinforcing alone), KQ (kidney reinforcing and Qi tonifying), KC (kidney reinforcing
and blood circulation invigorating), positive control and normal control groups was performed before and 3 and 6 months after treatment.
Patients in the TCM treated groups were treated with modified "Yougui decoction", with the addition of kidney Yin tonifying herbs in KA
group, Qi tonifying herbs in KQ group and blood circulation invigorating herbs in KC group. Patients in positive control group were treat-
ed with western medicine alone (androgen with or without cyclosporine A for six months). IFN: interferon; IL: interleukin; TNF: tumor
necrosis factor; TCM: Traditional Chinese Medicine. aP < 0.05, dP < 0.01, compared with that before treatment in the same group; bP <
0.05, compared with that after 3 months' treatment in the same group; cP < 0.05, compared with that in the normal control group; eP <
0.05, compared with that in the positive control group at the same time.
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panied by deficiency syndrome and stasis syndrome,
which challenges the therapeutic effects of treatment.
Qi works with the assistance of Yang; CAA patients
with kidney Yang deficiency also suffer from Qi defi-
ciency.9 Attributed to the stasis of blood in marrow, the
production of "fresh blood" is always impaired as well.
Besides kidney reinforcing, Qi tonifying and blood acti-
vating have already been applied in clinical practice,10,11
while no control study has been conducted and no fur-
ther mechanism explored.
We found that improvement of WBC and Hb counts
was quicker in the KQ group than the KA and KC
groups combined when compared with the positive
control group, while platelet count only increased in
the KC group. The recovery of hemograms was consis-
tent with the therapeutic effect in Western Medicine.
Patients in the KQ group had a 61.3% OE in 3
months, which was higher than in the positive control
group (33.3%, P < 0.05). After 6 months, all groups
showed improved OE, while only in the KC group, the
index was significantly higher than in the positive con-
trol group (80% vs 50%, P < 0.05). In addition, the
TCM syndrome scores in the KQ and KC groups also
decreased significantly when compared with the posi-
tive control group after 6 months, while the therapeu-
tic effect in TCM improved significantly only in the
KQ group. Our results showed that the treatment
based on kidney reinforcing and Qi tonifying achieved
a quicker and greater therapeutic effect in CAA, al-
though no differences were observed among the differ-
ent TCM groups combined. The treatment based on
kidney reinforcing and blood circulation invigorating
may have a better effect on platelet recovery when com-
pared with other TCM groups.
It is confirmed that immune disorders play a crucial
role in the onset and development of AA. The imbal-
ance between cytotoxic and T helper (Th) cells leads to
hyperactivity of cytotoxic T cells, which secrete cyto-
kines that inhibit the process of hematopoiesis and in-
duce apoptosis of stem cells, such as TNF-α and
IFN-γ.12,13 According to TCM theory, we know that
with "vital Qi" inside, no "evil" comes near. Treatment
by strengthening vital Qi may work by modulating the
immune function, which may also favor recovery from
CAA. The results showed that the treatment based on
TCM had a better effect on decreasing the ratio of cy-
totoxic T cells than the positive control group (P <
0.01), and KC may have had an advantage in increas-
ing the ratio of Th cells (P < 0.05). The regulation of T
cells may not be the therapeutic target of TCM in
CAA, for no prominent differences were observed
among the groups after 6 months.
In our study, patients with CAA had significantly high-
er levels of IL-2 and IL-4 when compared with those
in the normal control group. IL-2 is secreted by CD4+
Th1 cells, which may promote the proliferation of cyto-
toxic T cells, while IL-4 is secreted by CD4+ Th2 cells
and causes downregulation.14 Increases in IL-4 levels
may be the inverse feedback of the body to stop the ex-
cursion of Th1 cells in CAA. TCM had a role in de-
creasing the levels of IFN-γ, IL-2 and IL-6, as well as
promoting secretion of IL-4 (P < 0.05), which had a
positive correlation with the treatment course. IL-6 de-
creased significantly in the KQ and KC groups when
compared with the positive control group, indicating
that IL-6 may be the target of KQ and KC in the treat-
ment of CAA.
Gastrointestinal adverse reaction, polytrichia, gingival
hyperplasia, and rash are the most common side effects
of taking cyclosporine or androgens, which are also the
factors that affect patient compliance in clinical prac-
tice.15,16 Our study indicated that the treatment of
TCM had a role in decreasing the incidence of gastro-
intestinal adverse reaction, polytrichia, and rash, and
treatment with kidney reinforcing and blood circula-
tion invigorating may also contribute to the reduction
of liver dysfunction and hand tremor.
Table 8 Comparison of side effects in different groups [n (%)]
Side effect
Gastrointestinal reaction
Secondary hypertension
Polytrichia
Gingival hyperplasia
Rash
Liver dysfunction
Renal dysfunction
Hand tremor
KA group
5 (15.2)a
3 (9.1)
8 (24.2)b
7 (21.2)
5 (15.2)b
2 (6.1)
1 (3.0)
1 (3.0)
KQ group
4 (12.9)b
3 (9.7)
6 (19.4)b
6 (19.4)
5 (16.1)b
1 (3.2)
0 (0)
1 (3.2)
KC group
4 (13.3)b
2 (6.7)
7 (23.3)b
7 (23.3)
4 (13.3)b
0 (0)a
0 (0)
0 (0)a
Positive control group
8 (50)
2 (12.5)
10 (62.5)
6 (37.5)
9 (48.6)
3 (18.75)
1 (6.25)
3 (18.75)
Notes: side effects in the KA (kidney reinforcing alone), KQ (kidney reinforcing and Qi tonifying), KC (kidney reinforcing and blood cir-
culation invigorating) and positive control groups were evaluated in the course of the treatment. Patients in the TCM treated groups were
treated with modified "Yougui decoction", with the addition of kidney Yin tonifying herbs in KA group, Qi tonifying herbs in KQ group
and blood circulation invigorating herbs in KC group. Patients in positive control group were treated with western medicine alone (andro-
gen with or without cyclosporine A for six months). TCM: Traditional Chinese Medicine. aP < 0.05, bP < 0.05, compared with that in the
positive control group.
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Our results lead us to the conclusion that a combina-
tion of TCM therapies has a positive role in CAA,
which can exert an effect on rebalancing the cytotoxic
and Th cells, and regulate the expression of IFN-γ,
IL-2, IL-4 and IL-6. Among the three different TCM
principles of treatment, kidney reinforcing and Qi toni-
fying may have a better treatment profile, while treat-
ment with kidney reinforcing and blood circulation in-
vigorating may have an advantage in the recovery of
platelet levels. The results remind us that treatment
with kidney reinforcing, Qi tonifying, and blood circu-
lation invigorating should be considered in clinical
practice, especially the combination of the first two,
and more research is needed to confirm and explore
the underlying mechanisms of the treatments.
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